Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 10/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | OGG1 | O15527 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21148419 | 0.95 | KDM4E (0.59) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL10597687 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL29791099 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL2033775 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL28354466 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL10030191 | 0.84 | TDP1 (0.55) | KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL10534409 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL10391163 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL19844156 | 0.83 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDTDP1HTR1B | |
| SCHEMBL3433394 | 0.83 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDTDP1HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| WO-2006055140-A1 | ENCAPSULATED LIGHT EMITTING DIODES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060105483-A1 | Encapsulated light emitting diodes and methods of making | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | OAT, HAVCR2, OTC | KDM4E 4464/4885ALDH1A1 1477/4885HPGD 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.